Investigating Potential Securities Violations at uniQure
Block & Leviton is actively investigating uniQure N.V. (NASDAQ: QURE) regarding potential violations of securities law. This inquiry follows significant losses faced by investors in the company when shares plummeted following revelations about its gene therapy for Huntington's disease. Investors who think they have suffered losses as a result of their investment in uniQure are encouraged to reach out for support information on recovering their losses.
What Sparked the Investigation?
Details of the Share Decline
On a recent Monday, shares of uniQure experienced a staggering decline of up to 66%. This dramatic fall was prompted by announcements that the FDA considered the clinical data for their experimental gene therapy inadequate. Analysts were astonished by this news, as it indicated a significant change from previous communications the company had with regulators. Consequently, Block & Leviton is scrutinizing uniQure's disclosure practices and the adequacy of the information provided to investors.
Who Can Participate in the Investigation?
Identifying Affected Investors
Individuals who have invested in common stock of uniQure and witnessed a decline in their share value may qualify for participation in this investigation, regardless of whether they have sold their stocks. This opportunity extends to all investors who feel impacted by the company's recent actions.
The Role of Block & Leviton
What Actions are Being Taken?
Block & Leviton aims to establish whether uniQure engaged in securities law violations and may proceed with formal actions to recover losses suffered by investors. This investigation signifies the firm's proactive stance in advocating for the rights of investors affected by potential corporate misconduct.
How to Proceed if You’ve Been Affected
Next Steps for Affected Investors
If you are one of the many investors who have faced a financial setback due to your investment in uniQure, it is essential to contact Block & Leviton. They can provide insights into how to initiate a claim and explore options for potential compensation. You can reach them via their designated case website, by email, or phone.
Whistleblower Information
Confidential Reporting for Insiders
Individuals with non-public information regarding uniQure are encouraged to assist in the investigation. Collaborating with attorneys or filing a report under the SEC's whistleblower program can lead to potential rewards should the information provided result in a successful recovery. Block & Leviton welcomes communication from whistleblowers who wish to bring light to critical but unresolved issues surrounding the company.
Contact Information
Why Reach Out to Block & Leviton?
Recognized as a top-tier securities class action law firm, Block & Leviton has a proven track record of securing substantial recoveries for investors who have been defrauded. Committed to representing clients' interests vigorously, the firm actively engages in litigation across federal jurisdictions. Should you have questions or wish to learn more about the investigation, you can visit their website or contact them directly.
Frequently Asked Questions
What is the reason for the investigation into uniQure?
The investigation concerns potential securities law violations following a significant decline in stock value after adverse FDA news regarding the company's gene therapy.
Who can join the investigation?
Any investor who purchased uniQure shares and has experienced financial loss may be eligible to participate.
What actions is Block & Leviton taking?
They are investigating uniQure for potential law violations and pursuing actions to recover investor losses.
How do I contact Block & Leviton?
Investors can reach Block & Leviton through their website, via email, or by phone for assistance regarding the situation.
Can whistleblowers report non-public information?
Yes, whistleblowers with relevant information about uniQure can assist in the investigation and have the potential to receive rewards from the SEC.
